COMP <GO>
EHC vs LLY // GROSS PROFIT MARGIN
Encompass Health Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: EHC 6
— LLY 8
▲ GROSS PROFIT MARGIN LEADER: LLY
LAST: $135.90 (+3.35%) • MKT CAP: $12.97B
gross-margins
41.00%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 32.36% | -18.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 36.4x | -20.62 | EHC | /valuation <GO> |
| Free Cash Flow Yield | 2.92% | 2.30% | +0.62 | EHC | /fcf-yield <GO> |
| Operating Margin | 11.60% | 40.21% | -28.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 9.50% | 31.90% | -22.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 10.50% | 45.51% | -35.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 0.49% | +0.06 | EHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.47 | 9.29 | -5.82 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | EHC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.2 | 77.9 | -8.65 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 0.51 | +0.39 | EHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.3x | 26.3x | -4.95 | EHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.97B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EHC REV | LLY REV | EHC GROSS % | LLY GROSS % | EHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.94B | $65.18B | 44.0% | 83.0% | $367.1M | $16.81B |
| FY 2024 | $5.37B | $45.04B | 44.0% | 81.3% | $268.6M | $8.82B |
| FY 2023 | $4.80B | $34.12B | 44.0% | 79.3% | $178.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EHC // BETA 0.90
LLY // BETA 0.51